Jedan od glavnih ciljeva Life4me+ — jeste da spreči nove slučajeve HIV-a i ostalih polno prenosivih infekcija, hepatitisa C i tuberkuloze.

Aplikacija pomaže da se uspostavi anonimna komunikacija između lekara i osoba koje žive sa HIV-om. Omogućava da lakše organizujete Vaš raspored upotrebe lekova i da postavite prikrivene i personalizovane podsetnike.

Sve vesti / Mart 2019

Arhiviraj

✕

19 март 2019

6439

Descovy is not inferior to Truvada as a daily PrEP

Descovy is not inferior to Truvada as a daily PrEP

Descovy's daily supplement, which contains a newer version of tenofovir combined with emtricitabine, has a comparable protective effect with the traditional pre-exposure prophylaxis of HIV infection, including tenofovir and emtricitabine (Truvada), said Dr. Brad Hear of ...

18 март 2019

4844

The effectiveness of doravirine in combination with other ARVTs is not inferior to DRV + r / EFV

The effectiveness of doravirine in combination with other ARVTs is not inferior to DRV + r / EFV

#ART drug doravirin (DOR) as part of a 3-component therapy regimen HIV-1 is comparable in effectiveness to the combination of darunavir plus ritonavir (DRV + r) and efavirenza (EFV), follows from preliminary results of two ongoing clinical phase studies III DRIVE-FORWARD ...

17 март 2019

5480

TAF as PrEP: is efficiency a matter of form?

TAF as PrEP: is efficiency a matter of form?

Two studies of experimental pre-exposure prophylaxis schemes for HIV infection (PrEP) using the drug tenofovir alafenamide (TAF) immediately confirmed the effectiveness of therapy, but yielded conflicting results. According to experts who presented data at the Conference ...

16 март 2019

7623

On CROI were presented the latest data of the effectiveness and safety of fostemsavir

On CROI were presented the latest data of the effectiveness and safety of fostemsavir

On CROI were presented the latest information on studies of fostemsavir, a drug for the treatment of HIV infection of a fundamentally new type. Fostemsavir (FTR) is the first in its class prodrug of the Temsavir attachment inhibitor (TMR). TMR binds to HIV-1 by blocking ...

15 март 2019

5380

One in six South Africans has potential viral resistance to ART

One in six South Africans has potential viral resistance to ART

At the Conference on Retroviruses and Opportunistic Infections (CROI2019), was announced that up to 17% of South African people who had not previously been treated and who had evaded testing for HIV could have a drug-resistant strain of the virus, and more than half of those ...

14 март 2019

5916

MK-8591 implant has been shown to be highly effective at low dosages

MK-8591 implant has been shown to be highly effective at low dosages

#Merck's nucleoside reverse transcriptase translocation inhibitor (NRTTI) MK-8591 (outside the US and Canada - MSD) showed high antiviral activity against HIV-1 with a single dose of 0.5 mg, follows from preliminary results of clinical phase II trials (NCT03272347) presented ...

13 март 2019

5332

Second Generation HIV Maturation Inhibitor Presented in USA

Second Generation HIV Maturation Inhibitor Presented in USA

Dr. Edwin De Jesus of the Orlandian Center for Immunology (USA) last week presented the results of a phase IIa clinical trial of an innovative second-generation HIV maturation inhibitor GSK2838232. The drug, which previously demonstrated a clearly defined preclinical virological ...

12 март 2019

6751

Gilead presented data on the safety of its long-acting ARV drug

Gilead presented data on the safety of its long-acting ARV drug

Last Thursday, March 7, on the closing day of the International Conference on Retroviruses and Opportunistic Infections (CROI2019), the first data on the safety and tolerability of a fundamentally new ART-medication of prolonged action GS-6207 were presented. The development ...

9 март 2019

6138

Mortality from breast cancer is more common among women with HIV

Mortality from breast cancer is more common among women with HIV

According to a cohort study presented at the Conference on Retroviruses and Opportunistic Infections (CROI2019) in Seattle, the mortality rate among HIV-positive women with breast cancer (BC) is higher than among those with a negative status.

8 март 2019

5516

Test and Treat Principle Reduces the Number of New HIV Cases in South Africa by 30%

Test and Treat Principle Reduces the Number of New HIV Cases in South Africa by 30%

According to the latest data presented at the Conference on Retroviruses and Opportunistic Infections (CROI2019), the number of new HIV infections in southern Africa can be significantly reduced by voluntary testing for HIV in communities and immediately sending to treatment ...

1 2 3